Breast Cancer Research : Bcr
Overview
Breast Cancer Research (BCR) is a renowned scientific journal dedicated to advancing knowledge and understanding of breast cancer. It publishes cutting-edge research articles, reviews, and commentaries that cover various aspects of breast cancer, including its etiology, prevention, diagnosis, treatment, and survivorship. BCR serves as a valuable resource for researchers, clinicians, and healthcare professionals, contributing to the ongoing efforts in improving patient outcomes and ultimately finding a cure for this prevalent disease.
Details
Details
Abbr.
Breast Cancer Res
Start
1999
End
Continuing
Frequency
Bimonthly
p-ISSN
1465-5411
e-ISSN
1465-542X
Country
United Kingdom
Language
English
Specialty
Oncology
Metrics
Metrics
h-index / Ranks: 1006
175
SJR / Ranks: 790
2578
CiteScore / Ranks: 731
13.80
JIF / Ranks: 780
7.4
Recent Articles
11.
Shi Q, Yang W, Ouyang Y, Liu Y, Cai Z
Breast Cancer Res
. 2025 Feb;
27(1):28.
PMID: 40001186
No abstract available.
12.
Wu X, Xia Y, Lou X, Huang K, Wu L, Gao C
Breast Cancer Res
. 2025 Feb;
27(1):29.
PMID: 40001088
Background: Radiomics and AI have been widely used in breast cancer imaging, but a comprehensive systematic analysis is lacking. Therefore, this study aims to conduct a bibliometrics analysis in this...
13.
Marks J, Zhang D, Hardman T, Chen Y, Hall A, Simpson L, et al.
Breast Cancer Res
. 2025 Feb;
27(1):26.
PMID: 39980051
Purpose: CALGB 40903 (Alliance) was a phase II single arm multicenter trial conducted in postmenopausal patients diagnosed with estrogen-receptor (ER) positive breast ductal carcinoma in situ (DCIS) without invasion. Patients...
14.
Duivon M, Christy F, Thomas E, Lequesne J, Castel H, Gaudin C, et al.
Breast Cancer Res
. 2025 Feb;
27(1):25.
PMID: 39972319
Background: Apolipoprotein Ɛ4 genotype (APOE4) has been associated with cancer-related cognitive impairment, but its interaction with treatments remains unclear. This longitudinal study aims to evaluate the association between APOE4 and...
15.
Sabeti S, Larson N, Boughey J, Stan D, Solanki M, Fazzio R, et al.
Breast Cancer Res
. 2025 Feb;
27(1):24.
PMID: 39962614
Background: Angiogenic activity of cancerous breast tumors can be impacted by neoadjuvant chemotherapy (NAC), thus potentially serving as a marker for response monitoring. While different imaging modalities can aid in...
16.
Hunter N, Peterson L, Specht J, Mankoff D, Muzi M, Chen D, et al.
Breast Cancer Res
. 2025 Feb;
27(1):23.
PMID: 39962532
Background: F-Fluorodeoxyglucose (FDG) and F-Fluorestradiol (FES) have been FDA approved for measuring tumor glycolytic activity and estrogen receptor (ER) uptake, respectively, in clinical positron emission tomography (PET) imaging for patients...
17.
Schmidt G, Gluz O, Christgen M, Reinisch M, Kummel S, Nitz U, et al.
Breast Cancer Res
. 2025 Feb;
27(1):22.
PMID: 39953511
Background: New data show that not only HER2-overexpressing breast cancer (BC) tumors but also HER2-low tumors, classically considered as HER2-negative, respond to HER2-targeting antibody-drug-conjugates. Our objective was to analyze the...
18.
Zhang L, Liu Y, Yang C, Ma J, Li Y, Luo R, et al.
Breast Cancer Res
. 2025 Feb;
27(1):21.
PMID: 39948624
Background: Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer is the most common subtype of breast cancer, yet its response to traditional chemotherapy remains limited, posing a challenge...
19.
Yang J, Cao J, Sun R, Zhou X, Chen Z, Liu B, et al.
Breast Cancer Res
. 2025 Feb;
27(1):20.
PMID: 39930544
Background: Breast cancer is the leading cause of female mortality worldwide. (SET And MYND Domain Containing 4) SMYD4 has been reported to be a tumour suppressor. However, the molecular mechanism...
20.
Lopez M, Spehner L, Andre F, Viot J, Seffar E, Marguier A, et al.
Breast Cancer Res
. 2025 Feb;
27(1):19.
PMID: 39920833
Background: Breast Cancer (BC) is the most common type of cancer in women around the world and 70% of cases are hormone-receptor positive (HR+). In 40% of cases, a key...